Skeletal-related events occurred in 38% of patients with metastatic castration-resistant prostate cancer.
Skeletal-related events (SREs) are associated with increased mortality in men with bone metastatic castration-resistant prostate cancer (mCRPC), according to study findings published online in Prostate Cancer and Prostatic Diseases.
The study, by Lauren E. Howard, MD, of Duke University School of Medicine in Durham, North Carolina, and colleagues, included 233 men with nonmetastatic castration-resistant prostate cancer who later progressed to bone metastases. During follow-up, SREs occurred in 88 patients (38%) and 198 (85%) died. SREs were associated with a 67% increased mortality risk, after adjusting for age, race, biopsy Gleason score, primary treatment to the prostate, PSA, and other covariates. the researchers reported. After adjusting for bone pain, SREs were associated with a 42% increased risk.
The researchers noted that SREs, including pathologic fracture, spinal cord compression, radiation and surgery to bone, are common in bone mCRPC patients.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.